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Colorectal cancerAn international panel of multidisciplinary experts convened to develop recommendations for managing
patients with colorectal cancer (CRC) and synchronous liver metastases (CRCLM). A modiﬁed Delphi
method was used. CRCLM is deﬁned as liver metastases detected at or before diagnosis of the primary
CRC. Early and late metachronous metastases are deﬁned as those detected 612 months and >12 months
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Surgery
Synchronous colorectal liver metastases
Systemic therapyand alongside CT in difﬁcult situations. To evaluate operability, radiology should provide information on:
nodule size and number, segmental localization and relationship with major vessels, response after
neoadjuvant chemotherapy, non-tumoral liver condition and anticipated remnant liver volume.
Pathological evaluation should assess response to preoperative chemotherapy for both the primary
tumour and metastases, and provide information on the tumour, margin size and micrometastases.
Although the treatment strategy depends on the clinical scenario, the consensus was for chemotherapy
before surgery in most cases. When the primary CRC is asymptomatic, liver surgery may be performed
ﬁrst (reverse approach). When CRCLM are unresectable, the goal of preoperative chemotherapy is to
downsize tumours to allow resection. Hepatic resection should not be denied to patients with stable
disease after optimal chemotherapy, provided an adequate liver remnant with inﬂow and outﬂow
preservation remains. All patients with synchronous CRCLM should be evaluated by a hepatobiliary
multidisciplinary team.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Colorectal cancer (CRC) has become the third most common
malignancy worldwide in terms of incidence and fourth for cancer
mortality [1]. At CRC diagnosis, 20–25% of patients have stage IV
disease [2–5], in which synchronous CRC liver metastases (CRCLM)
are present in 15–25% of cases [6] and metastases are conﬁned to
the liver in 70–80% of these cases [7]. Surgical resection is the most
effective treatment approach for CRCLM, but only a minority of
patients are suitable for upfront surgery [8]. Although data from
the population-based Burgundy registry have to be interpreted
with caution as they are from the period 1976 to 2000, they show
that resection for cure of CRCLM is performed signiﬁcantly less
often in cases of synchronous metastases than for metachronous
metastases (6.3% vs 16.9%, respectively) [7]. The prognosis for
patients with untreated CRCLM is poor; in the Burgundy registry,
fewer than 30% of patients with untreated disease were alive after
1 year and fewer than 5% survived 5 years after diagnosis [7]. Data
from this registry also showed that 5-year survival rates were
shorter with synchronous than with metachronous CRCLM (3.3%
vs 6.1%, respectively) [7], although some studies have shown no
signiﬁcant difference [9]. The reported percentage of synchronous
CRCLM is increasing compared with metachronous metastases
[10], probably due to improved imaging techniques leading to ear-
lier diagnosis. However, different deﬁnitions of synchronous
metastases can be found in the literature and adoption of a stan-
dardized deﬁnition is needed to clarify future reporting.
An international multidisciplinary group of experts in managing
liver metastases (LM) from CRC (the EGOSLIM group) convened to
discuss synchronous metastases and their management. In the
absence of data from randomized controlled trials (RCTs) to guide
decisions, the aims of the meeting were to agree: a deﬁnition for
synchronous CRCLM; imaging for their detection; pathological
evaluation and reporting; resectability of CRCLM; timing for
surgery of the primary tumour and CRCLM; chemotherapy and
treatment regimens; postoperative management; and themultidis-
ciplinary approach to management. Through dissemination of the
consensus decisions reached, it is hoped that the management of
patients with synchronous CRCLM will be optimized.Methods
The international consensus panel comprised experts from the
USA, Europe and Asia in the treatment of patients with CRCLM
and included one coordinator, ﬁve medical oncologists (including
two gastroenterologists), ﬁve hepatic surgeons, one colorectal sur-
geon, two radiologists, one pathologist and one molecular gastroin-
testinal oncologist. All important aspects of multidisciplinary team
(MDT) management of synchronous CRCLM were identiﬁed beforethe meeting by the coordinator and referred to experts for presen-
tation at the meeting. Meta-analyses, RCTs and studies evaluating
clinical practice in the management of synchronous CRCLM were
identiﬁed and reviewed before, and discussed during, the meeting.
A modiﬁed Delphi method was used to aid achievement of a con-
sensus (see Appendix 1) [11]. Recommendations were formulated
when approved by all or a large majority of the panel members
and are summarized in Table 1. Strength of recommendations
was attributed based on the Strength of Recommendation Taxon-
omy [12]. For all recommendations, there is an assumption that
all imaging, surgery and therapy are optimal. Some panel members
were not present for the whole meeting and some members chose
to abstain from voting on some questions not in their area of
expertise.
Deﬁnition and prognosis of synchronous LM
Different deﬁnitions of synchronous CRCLM exist. Although, by
deﬁnition, all metastases are synchronous (occult or detectable at
diagnosis), most deﬁnitions include detection at or before diagno-
sis or surgery of the primary tumour [13], whilst some also include
metastases detected up to 3 [14,15], 4 [16] or 6 months [17,18] fol-
lowing diagnosis.
With regard to prognosis of resected synchronous LM, a
disease-free interval from the primary to discovery of the LM of
less than 12 months has been associated with a hazard ratio of
1.3 for disease recurrence [19]. The majority of the panel (14/15,
93%) agreed that synchronicity is a sign of poor prognosis, irrespec-
tive of the treatment. In the ongoing LiverMetSurvey international
registry, an international registry of patients undergoing surgery
for CRCLM, [20], available current data show a signiﬁcant differ-
ence in survival when metastases are detected at or 1 month
before diagnosis vs 0–3 months after diagnosis (p < 0.0001);
5-year survival is 39% vs 44%, respectively (Fig. 1). Survival rates
are not signiﬁcantly different between patients in whom metas-
tases are detected at or 1 month before vs up to 6 months or 6–
12 months after diagnosis (Fig. 1). However, survival rates are sig-
niﬁcantly different between patient groups when metastases are
detected at or within 1 month before diagnosis vs more than
12 months after the primary diagnosis (p < 0.0001). Although lack-
ing conﬁrmatory molecular biological information, these data sup-
port the division of LM into those diagnosed at the following time
points: at or before the time of diagnosis; 0–12 months following
diagnosis; and more than 12 months following diagnosis.
Consensus recommendations
 Synchronous CRCLM have less favorable cancer biology and
expected survival than metachronous, particularly late meta-
chronous, metastases.
Table 1
Questions and subquestions addressed by the participants before and at the meeting, and a summary of the recommendations.
Question Subquestion/options Recommendation Strength of
recommendationa
What would you consider to be
the correct deﬁnition of
‘synchronous’ LM?
1. LM diagnosed strictly at the same time as the col-
orectal primary
2. LM diagnosed up to 3 months after the colorectal
primary
3. LM diagnosed up to 6 months after the colorectal
primary
4. LM diagnosed up to 12 months after the colorectal
primary
 Synchronous CRCLM should be termed ‘syn-
chronously detected liver metastases’. This is
deﬁned as LM detected at or before diagnosis
of the primary tumour
 Early metachronous metastases are considered
to be those detected within 12 months of diag-
nosis or surgery of the primary
 Late metachronous metastases are considered to
be those detected more than 12 months after
surgery
A
2. Is synchronicity of LM a sign of
poor prognosis regarding the
outcome, irrespective of the
treatment?
1. Yes
2. No
 Synchronicity is a sign of poor prognosis B
3. Clinical scenario 1: patients
with resectable LM and
asymptomatic CRC
A. Would you mainly consider:
1. Chemotherapy ﬁrst, OR
2. Resection of the primary ﬁrst, OR
3. Resection of the primary and LM in a one-stage
procedure?B. In this setting, if you have to choose,
what do you consider to be the most important
timing for chemotherapy?
1. Preoperative
2. Postoperative
3. Both pre- and postoperative
a. Is this true for all cases?
C. In this setting, do you think that the
chemotherapy regimen should be:
1. The same as for patients with more advanced
disease
2. Different and probably alleviated (e.g. without tar-
geted therapy)?
 Chemotherapy should be given preoperatively
unless surgery of the primary and LM is consid-
ered easy
 For rectal tumours, preoperative radiotherapy is
a standard of care, but not for high rectal
tumours or T2 tumours, and one-stage surgery
should not be performed
 For colonic primary tumours, one-stage surgery
is not advocated for tumours needing complex
surgery, in high-risk patients or when hepatec-
tomy would be major
 A total of 6 months of chemotherapy is recom-
mended, independently of whether given pre-
or postoperatively
 Postoperative chemotherapy can be different to
preoperative chemotherapy and may be less
intense
B
4. Clinical scenario 2: patients
with non-resectable LM and
asymptomatic CRC
A. Would you mainly consider:
1. Chemotherapy ﬁrst, OR
2. Resection of the primary ﬁrst?B. Do you consider,
in this setting, the use of a reverse strategy (begin-
ning with liver resection)
1. A good rationale
2. A poor rationale?
 Chemotherapy should be administered initially
with the aim of achieving resectability of CRCLM
 If CRCLM become resectable, a reverse strategy
should be advocated
 For rectal cancer, radiotherapy may be given
before chemotherapy, or after resection of LM
A
B
5. Clinical scenario 3: patients
with resectable LM and
symptomatic CRC
A. Would you mainly consider:
1. Chemotherapy ﬁrst, OR
2. Radiotherapy, OR
3. Resection of the primary ﬁrst, OR
4. Resection of the primary and LM in a one-stage
procedure?B. Would you investigate using a stent,
if technically possible?
1. Yes, sometimes
2. No, never
 For bleeding CRC, following transfusions, preop-
erative chemotherapy should be advocated
 For perforations, resection of the primary to
remove the tumour (right colon) or suture or
creating a stoma (left colon) is advocated
 For proven occlusion with distended evidence of
obstruction, resection of the primary should be
performed ﬁrst
 For occlusions, stents are an option but results
have been poor
A
6. Clinical scenario 4: patients
with non-resectable LM and
symptomatic CRC
A. Would you mainly consider:
1. Chemotherapy ﬁrst, OR
2. Resection of the primary ﬁrst?B. Would you inves-
tigate using a stent, if technically possible?
1. Yes, sometimes
2. No, never
 The aim of management is to make LM resect-
able; patients would be managed as for scenario
3
 Stents are not recommended unless there is a
chance for cure
B
7. What is your opinion of one-
stage resection of both the
primary tumour and LM?
1. Favorable in all possible cases
2. Reserved for limited hepatectomies
3. Reserved only for easy-to-operate colonic cancers
(excluding rectal)
 One-stage resection is not appropriate in all
cases
 When both the primary tumour and metastases
are resectable, simultaneous resection can be
performed in selected patients undergoing lim-
ited hepatectomy
A
8. Compared with separate
resections, do you consider a
one-stage procedure
1. Overall, more risky
2. No more risky?
 A one-stage procedure is considered more risky
than separate resections
A
9. Would your chemotherapy
regimen be different for
resectable and unresectable
synchronous metastases?
1. No, the same (doublets or doublets with targeted
therapy)
2. Stronger (e.g. triple or triple with targeted
therapy) for unresectable
3. Stronger for resectable
 The same chemotherapy regimen can be used
for resectable and unresectable synchronous
LMs
A
10. After R0 surgery of both
colorectal and liver tumours,
would you consider
chemotherapy?
1. Yes, routinely
2. No, never
3. Yes, in selected cases
 A total of 6 months of chemotherapy is recom-
mended, whether given preoperatively or
postoperatively
B
(continued on next page)
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Table 1 (continued)
Question Subquestion/options Recommendation Strength of
recommendationa
11. After R0 surgery of both
colorectal and liver tumours,
would you consider associated
targeted therapy?
1. Yes, routinely
2. No, never
3. Only in patients responding to preoperative tar-
geted therapy
 The use of targeted therapy (anti-EGFR and
VEGF monoclonal antibodies) following R0 sur-
gery is not advocated
A
CRC, colorectal cancer; EGFR, epidermal growth factor receptor; LM, liver metastases; VEGF, vascular endothelial growth factor.
a Attributed based on the Strength of Recommendation Taxonomy [12]: A, recommendation based on consistent and good-quality patient-oriented evidence; B,
recommendation based on inconsistent or limited-quality patient-oriented evidence; C, recommendation based on consensus, usual practice, opinion, disease-oriented
evidence or case series for studies of diagnosis, treatment, prevention or screening.
Fig. 1. Survival after liver resection for synchronous metastases in relation to the timing of diagnosis of the liver metastases.
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liver metastases’. This is deﬁned as LM detected at or before
diagnosis of the primary tumour.
 Early metachronous metastases are considered to be those
detected within 12 months after diagnosis or surgery of the
primary.
 Late metachronous metastases are considered to be those
detected more than 12 months after diagnosis or surgery of
the primary.
The role of imaging in the detection of synchronous CRCLM
Imaging is used to detect and characterize liver nodules and
evaluate resectability. Imaging modalities include ultrasound,
contrast-enhanced ultrasound, computed tomography (CT), mag-
netic resonance imaging (MRI) and positron emission tomography
(PET)-CT. The best methods for staging are CT and MRI. A review of
the literature indicates that MRI is more sensitive than CT forsubcentimetre liver lesions [21] and after neoadjuvant chemother-
apy [22], and that a thoraco-abdominal CT is the best option for ini-
tial staging [12]. Appraisal of published methods shows that a
quadri/triphasic technique, optimal contrast administration and
scanning parameters providing high spatial and contrast resolution
show superior CT accuracy than generally reported in the literature
[23–25,22]. Regardless of the technique, the need for high-quality
baseline imaging before any chemotherapy cannot be stressed
enough. Lesions are easier to see before chemotherapy and treat-
ment response helps in characterization. MRI should be performed
when characterization is difﬁcult (e.g. when there are many small
nodules including both metastatic and benign lesions) and when
the liver is fatty [26]. Given the current state of technical develop-
ment and experience, high-quality MRI and CT can be used for pre-
operative imaging.
In an RCT of patients with resectable CRCLM (not speciﬁcally
synchronous), the use of PET-CT compared with CT alone did not
result in signiﬁcant changes in surgical management [27]. A role
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[28,29]. Contrast-enhanced intraoperative ultrasound has been
shown to improve both the sensitivity of intraoperative ultra-
sonography to detect LM and the rate of complete resection of hep-
atic metastases in patients undergoing surgery for CRCLM after
chemotherapy [30].
Consensus recommendations
 The panel was unanimous that initial CT has to be performed
before and after injection of iodine contrast, and that the use
of a low dose to decrease irradiation exposure is not
appropriate.
 If synchronous CRCLM are initially resectable, liver MRI may be
performed in addition to the initial high-quality CT, depending
on local expertise and the clinical scenario.
 PET-CT may be useful for the detection of extrahepatic disease,
particularly in patients with recurrent disease or high tumour
load (multinodular and/or large metastases) or for whom difﬁ-
cult hepatic resections are planned.
Role of imaging in evaluating response to preoperative
treatment
Assessing the response to preoperative treatment (chemother-
apy with or without targeted agents) can be judged on tumour size
[31,32], morphologic changes unrelated to size [33–35] and meta-
bolic activity [36,37]. Change in size is a key indicator of response,
but limitations encountered with the Response Evaluation Criteria
In Solid Tumors (RECIST) have led investigators to explore alterna-
tive measures of the impact of chemotherapy on tumour size
[38,39] and to deﬁne new parameters such as early tumour shrink-
age and depth of response [40,41]. It has been shown that when
treatment includes biological agents, such as bevacizumab, size is
a poor predictor of outcome compared with non-size-based mor-
phological criteria [35,34]. PET-CT is increasingly used to measure
response in oncology, but its role when added to cross-sectional
imaging to assess response in CRC metastases needs to be further
explored [36,37].
Consensus recommendations
 The following information should be provided by the radiologist
for evaluating the response to treatment based on CT imaging:
s Response based on size criteria.
s Response based on morphological criteria.
s Assessment of steatosis and signs of portal hypertension.
s Evaluation of the predicted future liver remnant in the
preoperative setting.
 Liver MRI is useful in patients with steatosis and to characterize
unclear liver lesions, but the value of routine repeat MRI to eval-
uate response remains unclear.
Pathology and molecular biology
The role of pathology in the management of CRCLM, including
synchronous CRCLM, is important in: diagnosing the speciﬁc
tumour type; assessing the completeness of resection and tumour
response; determining non-tumoral injury or reaction to preoper-
ative chemotherapy; and deﬁning tumour behavior in terms of
lymphovascular invasion. Thereby, it provides an estimate of prog-
nosis based on the tumour biology coupled with speciﬁc identiﬁca-
tion of biomarkers, such as epidermal growth factor receptor
(EGFR, KRAS wild-type expression), vascular endothelial growth
factor (VEGF) and the VEGF receptor. As yet, no biological markerhas been identiﬁed that distinguishes synchronous metastases
from metachronous metastases. RAS (NRAS and KRAS) mutations
have been associated with worse disease-free and overall survival
following CRCLM resection, independent of anti-EGFR therapy
[42–44].
Identifying patterns of pathological tumour response to
chemotherapy is a standard assessment and may guide surgery.
The degree of pathological tumour response to chemotherapy is
used as a surrogate marker of chemotherapy efﬁcacy and of biolog-
ical behavior of the tumour, recurrence and survival outcomes. It
can also identify adverse effects of chemotherapy, such as
chemotherapy-associated sinusoidal injury [45] or steatohepatitis
[46]. A complete pathological response is reported in only about
10% of cases [47–50]. Tumour regression grade [49], percentage
of viable tumour cells [47] and the thickness of the tumour’s
peripheral rim (‘dangerous halo’) [50] have all been used to evalu-
ate pathological response. These criteria have been validated in
multicentre studies associating response and survival. All but halo
thickness have been shown to be prognostic for overall survival
[47,50,48,49,51]. Safe resection margins are a goal of therapy but
the optimal margin width remains to be determined; however,
most studies indicate a minimal margin of 1 mm [52]. Intrahepatic
micrometastases are only visible under a microscope and represent
tumour invasion of sinusoids, the portal vein, the hepatic vein, and
lymphatic and bile ducts [53,54]. Micrometastases are separated
from CRCLM by a thin rim of normal parenchyma. Their incidence
and distance from the tumour seem to increase with the size of
CRCLM [53,55–57], but they are usually located within 1 cm of
CRCLM. Micrometastases have been less frequently detected in
patients receiving preoperative chemotherapy (25%) than in
untreated patients (60%), but preoperative chemotherapy does
not signiﬁcantly reduce the distribution of micrometastases [53].
Several studies have shown micrometastases to have a negative
impact on outcomes [58,57,54].
It has been hypothesized that metachronous CRCLM have a dif-
ferent biology after failure of FOLFOX compared with after
5-ﬂuorouracil or no chemotherapy. Adjuvant FOLFOX has been
associated with a high rate of somatic mutations in CRCLM and
inferior outcomes after hepatectomy, including shorter
disease-free survival and overall survival, than in the other two
groups [59].Consensus recommendations
 A standardized pathological evaluation report should include
information on: the size of the tumour and margin size; toxic
effects of therapy on non-tumour tissue; and the presence of
micrometastases and a ‘dangerous halo’ (may indicate worse
overall disease biology).
 Safe resection margins are still a goal of therapy; a minimal sur-
gical clearance margin of 1 mm has been suggested as
sufﬁcient.
 No biological marker has yet been identiﬁed that distinguishes
the biology and prognosis of synchronous from metachronous
CRCLM.
 Tumour response to preoperative therapy is evaluated using
tumour regression grade and/or pathological response (percent-
age viable tumour cells). Other scoring systems are available
and have prognostic value.
 Molecular evaluation of LM is playing an increasing role in the
evaluation of the biology of CRCLM. RAS (NRAS and KRAS) muta-
tions have been associated with worse disease-free and overall
survival after CRCLM resection, independent of anti-EGFR
therapy.
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Preoperative chemotherapy for synchronous metastases was
advocated by all but one panel member. It was recognized that
more evidence is needed to support this non-surgical strategy
[60,61]. It has been suggested that preoperative chemotherapy
has the beneﬁt of downsizing unresectable metastases and increas-
ing resectability of originally unresectable metastases, but not of
resectable metastases [61]. It might also be useful for assessing
tumour sensitivity to chemotherapy in patients with advanced dis-
ease. Elevated levels of carcinoembryonic antigen have been
shown to be a marker of response to perioperative FOLFOX in
patients with resectable CRCLM, regardless of the number of meta-
static lesions [62]. One panel member favored liver resection ﬁrst
when disease is initially easily resectable.
Chemotherapy regimens for synchronous unresectable
metastases
Chemotherapy regimens in mCRC are now achieving high
response rates (>50%) and long median survival (30 months).
Any of the regimens used for the ﬁrst-line management of
advanced CRC are indicated in cases of synchronous LM, including
FOLFOXFIRI with or without bevacizumab or anti-EGFR therapy,
and doublets plus bevacizumab or anti-EGFR therapy [63–66]. In
patients not responding to ﬁrst-line chemotherapy, second-line
therapy for mCRC with FOLFIRI plus panitumumab can still elicit
a treatment response [67]. Resection is possible but not common
following second-line treatment [68,69]. Although there are no
evidence-based data to support the use of targeted therapies after
resection, if a regimen is effective in the preoperative setting, many
teams use the same regimen postoperatively.
Although upfront surgery of the primary tumour is advocated
by some [70], studies have shown that preoperative chemotherapy
can delay surgery of an asymptomatic primary tumour in patients
with synchronous CRCLM without compromising survival [71–73].
Data from the GERCOR database, and also from the Crystal and
OPUS studies, suggest that in patients with unresectable disease,
the response rate is higher in patients with liver-limited metas-
tases than in those with non-liver-limited metastases (personal
communication, Aimery de Gramont) [74]. GERCOR data also sug-
gest that response to second-line therapy does not depend on
response to ﬁrst-line therapy (personal communication, Aimery
de Gramont).
With longer overall and median survival rates, indications for
surgery are increasing, with R1 surgery (complete tumour resec-
tion without safe margins) being justiﬁed for patients with a
response to preoperative chemotherapy [75,76]. Following preop-
erative chemotherapy and resection, adjuvant chemotherapy
should be considered. The panel considered the optimal timing
for assessment of response to chemotherapy to be every 2 months.
These recommendations are in keeping with those from the
European Society for Medical Oncology for mCRC, which recommend
cytotoxic doublet plus targeted therapy for patients with poten-
tially resectable and unlikely resectable mCRC [77], and those of
the National Institute for Health and Care Excellence (NICE) in
England and Wales [78]. Overall, a total duration of 6 months of
perioperative (preoperative and adjuvant) chemotherapy is
recommended.
Consensus recommendations
 All but one panel member favored ﬁrst-line optimal chemother-
apy for patients with potentially resectable synchronous
metastatic disease. Optimal chemotherapy regimens for synchronous CRCLM
include doublets (e.g. FOLFOX, FOLFIRI) combined with targeted
therapy (e.g. bevacizumab, cetuximab, panitumumab, depend-
ing on RAS status), triplets (FOLFOXIRI) and triplets combined
with targeted therapy. However, there was a consensus that
chemotherapy without targeted therapy could be used for
patients with resectable CRCLM in the absence of evidence for
biological agents being useful in this setting.
 As advocated in earlier recommendations for synchronous
CRCLM, at least four courses of ﬁrst-line chemotherapy should
be given and, if progression occurs during ﬁrst-line therapy or
only stable disease is achieved after 4 months, second-line treat-
ment should be considered if conversion from borderline or
non-resectable metastases to resectability is still the goal [79].
 A sequential treatment approach (e.g. adding a third agent to a
doublet) may be used to treat patients who are unresponsive to
ﬁrst-line therapy.
 The optimal timing for assessing response to chemotherapy is
considered to be every 2 months.
 These recommendations are in line with those from the
European Society for Medical Oncology for mCRC, which recom-
mends cytotoxic doublet plus targeted therapy for patients with
potentially resectable and unlikely resectable mCRC [77], and
those of NICE in England and Wales [78].
 Overall, a total duration of 6 months of perioperative (preoper-
ative and adjuvant) chemotherapy is recommended.
Surgery of the primary tumour
Colorectal surgery should be performed by a specialist colorec-
tal surgeon. The quality of surgery is as important for tumours of
the rectum as it is for those of the colon and requires total meso-
colon/mesorectal excision, lymph node clearance and a good mar-
gin of resection. Based on preoperative staging, the surgeon must
be aware of the tumour margins before surgery. For rectal cancer,
most patients with synchronous CRCLM will have a local tumour
burden that requires radiotherapy.
When both the primary tumour and the metastases are resect-
able, simultaneous resection can be performed in selected patients
undergoing limited hepatectomy with similar outcomes to sequen-
tial surgery [80,81,13]. Simultaneous resection should be discour-
aged when the hepatectomy would be major (involving three or
more segments) or when complex rectal surgery is to be per-
formed, due to signiﬁcantly higher postoperative mortality and
morbidity [82].
Delaying hepatic resection does not impair survival and may
help select those patients most likely to beneﬁt from hepatic resec-
tion [83]. When CRC is asymptomatic, the decision for surgery
depends on the resectability of CRCLM. When CRCLM are
non-resectable, the beneﬁt of resection of the primary tumour
without liver resection is debatable, although the results of a
meta-analysis have shown a survival beneﬁt [84]; however, data
from this meta-analysis of non-randomized trials are questionable
due to potential publication biases. Several RCTs have been started
but most have not recruited a sufﬁcient number of patients, and
have been stopped prematurely [85].
Laparoscopy is increasingly being used and is generally feasible
for the colon and rectum, but is more difﬁcult if the tumour has
invaded adjacent organs or perforated the visceral peritoneum
(T4). Compared with conventional surgery, laparoscopy is associ-
ated with less pain, better pulmonary function, reduced fatigue,
shorter hospital stay and better quality of life [86,87]. Laparoscopic
surgery for colon and rectal cancer provides similar overall
and disease-free survival to open surgery [88]. In addition, the
incidence of sexual dysfunction and micturition symptoms
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to be similar to that following open surgery [89].Consensus recommendations
 Colorectal surgery should be performed by a specialist colorec-
tal surgeon.
 Laparoscopy is generally feasible for the colon and rectum, with
similar outcomes to open surgery, but is more difﬁcult if the
tumour has invaded adjacent organs or perforated the visceral
peritoneum (T4).
 For synchronous rectal LM, preoperative radiotherapy is recom-
mended for mid or low rectal tumours, but chemotherapy
remains an adequate treatment for LM.
 When both the primary tumour and the metastases are resect-
able and uncomplicated, simultaneous resection can be per-
formed in selected patients undergoing limited hepatectomy.
 When synchronous CRCLM are non-resectable, resection of the
asymptomatic primary without liver resection might have
beneﬁts.
Surgery of the liver
The classical approach to surgery of synchronous CRCLM has
been to perform primary surgery on the primary CRC followed by
resection of LM 2–3 months later, with or without chemotherapy
in the interval between surgeries. Currently, preoperative
chemotherapy is increasingly being used and, if the CRC is asymp-
tomatic, may be administered before surgery of the primary
tumour with the aim of downsizing the metastases and improving
resectability rates. As mentioned above, simultaneous resections
for CRC and synchronous LM have been shown to be favorable in
a number of studies, although caution should be exercised for
major combined resections or in patients with comorbid condi-
tions, due to the higher risk of mortality and complications related
to simultaneous surgery in this setting [80,81,13,82].
When the primary CRC is asymptomatic, and in particular for
those patients requiring neoadjuvant radiotherapy for rectal can-
cer, liver surgery might be performed ﬁrst (reverse approach). If
both primary rectal cancer radiation and CRCLM chemotherapy
are required, initial short-course (5  5 Gy) radiation followed by
chemotherapy is recommended. Preoperative chemotherapy is
advised to downsize synchronous CRCLM for resection, to mini-
mize the risk of synchronous CRCLM progressing beyond the pos-
sibility of cure and to minimize the occurrence of new
metastases [90]. Resection of CRCLM should be performed as soon
as it appears feasible after tumour shrinkage [91]. When patients
receive more than 6 months of aggressive chemotherapy, the risk
associated with surgery is increased [92]. Similar outcomes have
been reported for patients undergoing a classic (CRC ﬁrst), com-
bined or reverse (liver-ﬁrst) surgical strategy for synchronous
CRCLM [93].
Hepatic resection should not be denied to patients with stable
disease after optimum chemotherapy, provided there is adequate
liver remnant with inﬂow and outﬂow preservation. This may be
achieved, for example, through advanced techniques such as portal
and/or hepatic venous embolization or two-stage hepatectomy
[94–96]. Associating liver partition and portal vein ligation for
staged hepatectomy (ALPPS) to induce growth of the future liver
remnant before liver resections is being investigated, but results
to date indicate increased complications and mortality [97]. Data
on overall and long-term survival with ALPPS are needed.
In Asia, resectable synchronous CRCLM are more likely to be
indicated for upfront simultaneous resection (before chemother-
apy) [98], whereas in Westernized countries, chemotherapy ﬁrstis the preferred option [78,77]. One-stage surgery is more fre-
quently performed in Asia, with acceptable short-term outcomes.
Consensus recommendations
 Simultaneous surgery of the primary tumour and CRCLM should
be reserved for selected patients with both resectable lesions
and requiring limited surgical procedures.
 Preoperative chemotherapy is usually advised to control the
metastatic disease and to downsize synchronous CRCLM for
resection.
 The reverse approach (i.e. liver surgery performed ﬁrst) may be
used after preoperative chemotherapy when the CRCLM tumour
burden is large and combined resection is not possible.
 Hepatic resection should not be denied to patients with stable
disease after optimum chemotherapy, provided there is ade-
quate liver remnant with vascular inﬂow and outﬂow
preservation.
o This may be achieved through speciﬁc techniques aimed to
increase resectability.
Multidisciplinary teams
The last few years have seen a greater awareness of the impor-
tance of MDTs. Results from a ﬁrst prospective study to evaluate
the MDT discussion process and its effects on treatment
approaches for a variety of gastrointestinal cancers at a US cancer
centre have recently been published [99]. Despite 84% of clinicians
being certain of their original plan, a change was recommended in
36% of cases, 72% of which involved major changes; there was 77%
adherence to the recommended treatments. The potential advan-
tages of an MDT include better patient care and survival outcomes,
and improved consistency, continuity, coordination and
cost-effectiveness of care [100–102]. Same-centre management
also has beneﬁts over referred-patient management, including a
reduced number of interventions, shorter delays in care, better
control of chemotherapy and decreased postoperative mortality
[103–105]. This could be of utmost importance in patients with
synchronous metastases.
Non-adherence to MDT decisions has been shown to result in a
trend toward lower survival rates in lung cancer [106]. A UK study
of non-adherence to MDT decisions (15.1% of decisions were not
implemented) in gastrointestinal surgery showed the main reasons
for non-adherence to be comorbid conditions (43.9%), patient
choice (34.2%) and more information becoming available (19.5%)
[107].
Consensus recommendations
 A proﬁcient MDT consisting of at least a colorectal surgeon, liver
surgeon, medical/gastrointestinal and radiation oncologist,
radiologist, nuclear medicine physician and pathologist opti-
mizes the treatment of CRCLM.
 The treatment should be considered as a whole, from diagnosis
to the last treatment at the same centre.
 It is important to evaluate and analyze the outcomes from
MDTs to assess improvements in treatment goals.
The critical impact of the expertise of the team for patient
management
Following the mandatory legal requirement for MDT manage-
ment of all cancer patients in the UK, France, Belgium, Spain and
a number of other European countries over the last 10–15 years,
there has been a signiﬁcant overall improvement in outcomes
for all patients with stage IV CRC [108,109]. A specialized MDT
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a general CRC MDT [110,111] and should include surgeons special-
izing in colorectal surgery, hepatobiliary surgery and thoracic
surgery, dedicated CRC medical and radiation oncologists, both
imaging and interventional radiologists, and dedicated CRC surgi-
cal pathologists.
Clinical scenario recommendations for synchronous CRCLM
In clinical practice, the main determinants of the
decision-making process are the tumour statuses of both the pri-
mary tumour and metastases and, more precisely, the need for
emergency surgery of a complicated primary tumour and the
resectability of both tumour sites.
Asymptomatic CRC and resectable synchronous CRCLM
This is the most favorable clinical scenario. A panel consensus
(10/11, 91%) was reached for chemotherapy to be given preopera-
tively. Four or six cycles of chemotherapy were recommended.
However, data from the LiverMetSurvey show that 5-year survival
is not better with chemotherapy ﬁrst than with surgery of the pri-
mary tumour ﬁrst (42% vs 47%, respectively) (Fig. 2). It is, however,
likely that surgery of the primary tumour ﬁrst could have been
reserved for selected patients with less widespread disease com-
pared with those treated with chemotherapy ﬁrst.
For mid and low rectal primary tumours, radiotherapy is often
needed and one-stage surgery should not be performed. For colonic
and upper rectal primary tumours, one-stage surgery is not
advocated for complex colonic tumours, for high-risk patients or
when hepatectomy is major (P3 segments). Data from the
LiverMetSurvey show that irrespective of the status of the primary
tumour, one-stage resection of both the primary tumour and
metastases is associated with worse 5-year survival (40%) com-
pared with liver-ﬁrst surgery (47%) or primary-ﬁrst surgery (44%)
(Fig. 3).
Most panel members (8/12, 67%) considered pre- and postoper-
ative chemotherapy to be equally important; 3/12 (25%) consid-
ered preoperative chemotherapy and 1/12 (8%) consideredFig. 2. Survival following liver resection for synchronous resectable metapostoperative chemotherapy to be most important. Most partici-
pants (9/11, 82%) considered that postoperative chemotherapy
could be different to preoperative chemotherapy, and probably less
intensive.
In summary, the recommended management is for chemother-
apy ﬁrst, with or without radiotherapy, followed either by surgery
in a one-stage procedure (for patients with limited hepatic disease
and easy-to-resect primary tumours) or by staged surgery (for
other patients). No strong evidence exists, however, to support this
expert recommendation of chemotherapy ﬁrst, as opposed to colon
resection ﬁrst.
Asymptomatic CRC and non-resectable synchronous CRCLM
This second scenario is one of the most frequently observed,
and has traditionally been managed with resection of the primary
tumour followed by chemotherapy and then surgery of metastases
when resectability can be obtained. Treatment has since evolved,
and the entire panel agreed that chemotherapy should be adminis-
tered initially with the aim of achieving resectability of CRCLM. For
potentially resectable disease, all were in favor of optimal
chemotherapy (doublets plus biologics, or triplets plus biologics).
Data from the LiverMetSurvey show no difference in 5-year sur-
vival rates between patients receiving chemotherapy ﬁrst and
those undergoing colectomy ﬁrst, before resection of CRCLM (31%
vs 33%, respectively) (Fig. 4). However, colectomy ﬁrst may have
been reserved for patients with the best prognosis, introducing a
bias into the analysis. Three ongoing trials are comparing the man-
agement strategies of colectomy ﬁrst vs chemotherapy ﬁrst.
All of the panel experts agreed that simultaneous surgery
should not be attempted. If CRCLM become resectable, all recom-
mended the reverse approach to surgery (i.e. liver ﬁrst). Data from
the LiverMetSurvey, although not signiﬁcantly different between
strategies, support this approach; 5-year survival rates were 42%
for the reverse approach compared with 33% for colon ﬁrst surgery
and 28% for one-stage surgery (Fig. 5). For rectal cancer, alternative
approaches are to begin with short-course radiotherapy for the pri-
mary cancer and then chemotherapy for downsizing CRCLM or to
administer primary optimal chemotherapy, then radiotherapystases in relation to ﬁrst treatment (colon surgery or chemotherapy).
Fig. 3. Survival after liver resection for synchronous resectable metastases in relation to the ﬁrst surgery (colon, liver or colon plus liver).
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resection of CRCLM. For primary colon or rectal tumours that
appear unresectable or borderline resectable, in the UK, NICE guid-
ance is that preoperative chemotherapy should not be offered
solely to facilitate sphincter-sparing surgery to patients with rectal
cancer [78].
In summary, the consensus is for optimal chemotherapy ﬁrst,
with the aim of making LM resectable. This should then be fol-
lowed by hepatic surgery and resection of the primary tumour.Fig. 4. Survival following liver resection for synchronous unresectable metSymptomatic CRC and resectable synchronous CRCLM
Patients with symptomatic CRC may have bleeding, obstruction
or perforation. Generally, bleeding can be managed with blood
transfusions and will often stop after chemotherapy treatment.
Most of the expert panel (9/12, 75%) were in agreement that
patients with bleeding should undergo preoperative chemother-
apy; the others (3/12, 25%) considered that resection of the pri-
mary tumour should be undertaken ﬁrst.astases in relation to ﬁrst treatment (colon surgery or chemotherapy).
Fig. 5. Survival following liver resection for synchronous unresectable metastases in relation to ﬁrst surgery (colon, liver or colon plus liver).
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tumour when it is easily resectable, such as right hemicolectomy
for right-sided colon lesions or sigmoid colectomy for sigmoid
lesions, or to create a stoma (left colon) in cases requiring more
technical surgery, such as low anterior resection syndrome and
total mesorectal excision. The panel was in complete agreement
that, if possible, resection of the primary tumour should be per-
formed ﬁrst under these circumstances.
Stents are an option for colorectal obstruction, but the results
have been poor and the panel recommended reserving them only
for easily resectable cases, particularly in elderly patients, and
not for right colon or rectal surgery or when anti-angiogenic agents
are used. This guidance is in line with that provided by the Endo-
scopy and Cancer Committee of the French Society of Digestive
Endoscopy and the French Federation of Digestive Oncology
[112] and with UK NICE guidance [78]. For clinically and radiolog-
ically proven complete occlusion with distended evidence of
obstruction, the panel was in complete agreement that resection
of the primary tumour should be performed ﬁrst; 9/11 (82%) would
perform surgery and use a stoma, whilst 2/11 (18%) would use a
stent.
In summary, recommendations are for resection of the primary
tumour for perforated or occlusive tumours (but not for tumours
with bleeding causing anaemia), followed by chemotherapy and
then surgery of LM.
Symptomatic CRC and non-resectable synchronous CRCLM
The expert panel considered that the aim of management for
patients with symptomatic CRC and non-resectable synchronous
CRCLM is to make the LM resectable. The use of stents is not
recommended in most patients owing to the high risk ofcomplications (e.g. perforation, migration bleeding, pain). As in
the previous clinical scenario, surgery of the primary tumour
should be reserved for cases of bowel perforation or occlusion,
with systemic chemotherapy used to downsize both metastases
and the primary tumour in other scenarios.
In summary, recommendations are for resection of the primary
tumour for perforated or occlusive tumours, followed by
chemotherapy and then surgery of LM if tumour shrinkage is
achieved. For tumours with bleeding causing anaemia, induction
chemotherapy is recommended to downsize both the primary
tumour and LM, followed by surgery of the site with the most sig-
niﬁcant tumour load (usually the liver; i.e. reverse approach).
Conclusions
Synchronous CRCLM should be termed ‘synchronously detected
liver metastases’. This is deﬁned as LM detected at or before the
diagnosis of the primary tumour. Synchronous CRCLM may have
less favorable cancer biology and be associated with lower
expected survival compared with metachronous metastases. Initial
high-dose contrast-enhanced CT of the abdomen is recommended
to provide information on whether synchronous CRCLM are
resectable.
Recommendations have been made for the management of four
different clinical scenarios
1. For asymptomatic CRC and resectable synchronous CRCLM, the
recommended management is for chemotherapy ﬁrst, with or
without radiotherapy, followed either by surgery in a
one-stage procedure (for patients with limited hepatic disease
and easy-to-resect primary tumours) or by staged surgery (for
other patients). No strong evidence exists, however, to support
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to colon resection ﬁrst; ongoing trials may provide such
evidence.
2. For asymptomatic CRC and non-resectable synchronous CRCLM,
the consensus is for optimal chemotherapy ﬁrst, with the aim of
making LM resectable. This should then be followed by hepatic
surgery and resection of the primary tumour.
3. For symptomatic CRC and resectable synchronous CRCLM, rec-
ommendations are for resection of the primary tumour for per-
forated or occlusive tumours (but not for tumours with
bleeding causing anaemia), followed by chemotherapy and then
surgery of LM.
4. For symptomatic CRC and non-resectable synchronous CRCLM,
recommendations are for resection of the primary tumour for
perforated or occlusive tumours, followed by chemotherapy
and then surgery of LM if tumour shrinkage is achieved. For
tumours with bleeding causing anaemia, induction chemother-
apy is recommended to downsize both the primary tumour and
LM, followed by surgery of the site with the most signiﬁcant
tumour load (usually the liver; i.e. reverse approach).
At least four courses of ﬁrst-line optimal chemotherapy (dou-
blets with targeted therapy or triplets with or without targeted
therapy) are recommended for potentially resectable metastatic
disease, with assessment of response every 2 months and a total
(preoperative and adjuvant) duration of 6 months’ systemic ther-
apy. Intra-arterial chemotherapy may be an alternative option
and has been associated with good response rates.
It is hoped that the recommendations provided and the treat-
ment plans for the four different clinical scenarios should help to
raise the standard of care for patients with synchronous CRCLM.Author contributions
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